# Eyad Elkord

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 118 papers | 8,711 citations | 61857 43 h-index | 46693 89 g-index |
| 123 all docs | 123 docs citations | 123 times ranked | 13517 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Immune checkpoint inhibitors: recent progress and potential biomarkers. Experimental and Molecular Medicine, 2018, 50, 1-11. | 3.2 | 1,410 |
| 2 | Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Seminars in Cancer Biology, 2015, 35, S185-S198. | 4.3 | 1,122 |
| 3 | Significance of CD44 and CD24 as Cancer Stem Cell Markers: An Enduring Ambiguity. Clinical and Developmental Immunology, 2012, 2012, 1-11. | 3.3 | 385 |
| 4 | Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. Vaccines, 2016, 4, 28. | 2.1 | 372 |
| 5 | Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma. Clinical Cancer Research, 2010, 16, 1662-1672. | 3.2 | 236 |
| 6 | Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. British Journal of Cancer, 2010, 102, 1129-1136. | 2.9 | 225 |
| 7 | Immune checkpoint inhibitors in cancer therapy: a focus on Tâ€regulatory cells. Immunology and Cell Biology, 2018, 96, 21-33. | 1.0 | 225 |
| 8 | Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304. | 4.3 | 220 |
| 9 | Myeloidâ€derived suppressor cells in cancer: recent progress and prospects. Immunology and Cell Biology, 2013, 91, 493-502. | 1.0 | 196 |
| 10 | Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunology, Immunotherapy, 2014, 63, 81-99. | 2.0 | 181 |
| 11 | Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunology, Immunotherapy, 2007, 56, 1743-1753. | 2.0 | 177 |
| 12 | Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. Seminars in Cancer Biology, 2020, 65, 13-27. | 4.3 | 170 |
| 13 | FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets. Cancer Letters, 2020, 490, 174-185. | 3.2 | 169 |
| 14 | Tâ€cell responses and therapies against SARSâ€CoVâ€2 infection. Immunology, 2021, 162, 30-43. | 2.0 | 159 |
| 15 | Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Letters, 2019, 457, 168-179. | 3.2 | 148 |
| 16 | Single-Cell Transcriptome Analysis Highlights a Role for Neutrophils and Inflammatory Macrophages in the Pathogenesis of Severe COVID-19. Cells, 2020, 9, 2374. | 1.8 | 147 |
| 17 | Immune checkpoints in the tumor microenvironment. Seminars in Cancer Biology, 2020, 65, 1-12. | 4.3 | 146 |
| 18 | Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells. Immunology, 2005, 114, 204-212. | 2.0 | 134 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Increased Levels of Granulocytic Myeloid-Derived Suppressor Cells in Peripheral Blood and Tumour Tissue of Pancreatic Cancer Patients. Journal of Immunology Research, 2014, 2014, 1-9. | 0.9 | 109 |
| 20 | DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Clinical Epigenetics, 2018, 10, 78. | 1.8 | 103 |
| 21 | Immune Checkpoints in Circulating and Tumor-Infiltrating CD4+ T Cell Subsets in Colorectal Cancer Patients. Frontiers in Immunology, 2019, 10, 2936. | 2.2 | 97 |
| 22 | Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. Oncotarget, 2017, 8, 33159-33171. | 0.8 | 96 |
| 23 | T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opinion on Biological Therapy, 2010, 10, 1573-1586. | 1.4 | 94 |
| 24 | Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells. Expert Opinion on Therapeutic Targets, 2018, 22, 547-557. | 1.5 | 90 |
| 25 | Clinical and Immunologic Results of a Phase II Trial of Sequential Imiquimod and Photodynamic Therapy for Vulval Intraepithelial Neoplasia. Clinical Cancer Research, 2008, 14, 5292-5299. | 3.2 | 89 |
| 26 | Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP. Oncotarget, 2015, 6, 20026-20036. | 0.8 | 80 |
| 27 | Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer. Cancer Immunology, Immunotherapy, 2020, 69, 1989-1999. | 2.0 | 75 |
| 28 | Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clinical Immunology, 2011, 138, 85-96. | 1.4 | 69 |
| 29 | Salmonella-mediated tumor regression involves targeting of tumor myeloid suppressor cells causing a shift to M1-like phenotype and reduction in suppressive capacity. Cancer Immunology, Immunotherapy, 2014, 63, 587-599. | 2.0 | 69 |
| 30 | Intratumoral FoxP3+Helios+ Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer. Frontiers in Immunology, 2017, 8, 619. | 2.2 | 69 |
| 31 | DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. Clinical Epigenetics, 2018, 10, 104. | 1.8 | 68 |
| 32 | Helios Should Not Be Cited as a Marker of Human Thymus-Derived Tregs. Commentary: Helios+ and Heliosâ^' Cells Coexist within the Natural FOXP3+ T Regulatory Cell Subset in Humans. Frontiers in Immunology, 2016, 7, 276. | 2.2 | 64 |
| 33 | Myeloid cells in circulation and tumor microenvironment of breast cancer patients. Cancer Immunology, Immunotherapy, 2017, 66, 753-764. | 2.0 | 63 |
| 34 | Long non-coding RNA (lncRNA) transcriptional landscape in breast cancer identifies LINC01614 as non-favorable prognostic biomarker regulated by TGFÎ² and focal adhesion kinase (FAK) signaling. Cell Death Discovery, 2019, 5, 109. | 2.0 | 63 |
| 35 | Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells. Vaccines, 2019, 7, 149. | 2.1 | 63 |
| 36 | Increased Levels of Circulating and Tumor-Infiltrating Granulocytic Myeloid Cells in Colorectal Cancer Patients. Frontiers in Immunology, 2016, 7, 560. | 2.2 | 58 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression. Frontiers in Immunology, 2020, 11, 1469. | 2.2 | 58 |
| 38 | DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients. OncoImmunology, 2019, 8, e1542918. | 2.1 | 54 |
| 39 | Frequency of human T regulatory cells in peripheral blood is significantly reduced by cryopreservation. Journal of Immunological Methods, 2009, 347, 87-90. | 0.6 | 53 |
| 40 | Transcriptomic profiling disclosed the role of DNA methylation and histone modifications in tumor-infiltrating myeloid-derived suppressor cell subsets in colorectal cancer. Clinical Epigenetics, 2020, 12, 13. | 1.8 | 52 |
| 41 | PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer. Cancers, 2019, 11, 1050. | 1.7 | 50 |
| 42 | PD-L1 Expression in Human Breast Cancer Stem Cells Is Epigenetically Regulated through Posttranslational Histone Modifications. Journal of Oncology, 2019, 2019, 1-9. | 0.6 | 48 |
| 43 | An MVA-based Vaccine Targeting the Oncofetal Antigen 5T4 in Patients Undergoing Surgical Resection of Colorectal Cancer Liver Metastases. Journal of Immunotherapy, 2008, 31, 820-829. | 1.2 | 45 |
| 44 | Integrated Transcriptome and Pathway Analyses Revealed Multiple Activated Pathways in Breast Cancer. Frontiers in Oncology, 2019, 9, 910. | 1.3 | 44 |
| 45 | Therapeutic prospects of targeting myeloidâ€derived suppressor cells and immune checkpoints in cancer. Immunology and Cell Biology, 2018, 96, 888-897. | 1.0 | 43 |
| 46 | Expanded subpopulation of FoxP3+ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs. Clinical Immunology, 2011, 140, 218-222. | 1.4 | 42 |
| 47 | In-vitro effect of pembrolizumab on different T regulatory cell subsets. Clinical and Experimental Immunology, 2018, 191, 189-197. | 1.1 | 42 |
| 48 | T Cellâ€“Based Immunotherapy of Metastatic Renal Cell Carcinoma: Modest Success and Future Perspective. Clinical Cancer Research, 2009, 15, 6503-6510. | 3.2 | 35 |
| 49 | Adoptive transfer of Treg depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunology, Immunotherapy, 2008, 57, 623-634. | 2.0 | 34 |
| 50 | Transcriptomic Analyses Revealed Systemic Alterations in Gene Expression in Circulation and Tumor Microenvironment of Colorectal Cancer Patients. Cancers, 2019, 11, 1994. | 1.7 | 33 |
| 51 | Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Cancer Immunology, Immunotherapy, 2009, 58, 1657-1667. | 2.0 | 31 |
| 52 | Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients. Oncotarget, 2016, 7, 14083-14094. | 0.8 | 30 |
| 53 | Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. Expert Opinion on Biological Therapy, 2014, 14, 931-945. | 1.4 | 28 |
| 54 | Novel expression of Neuropilin 1 on human tumor-infiltrating lymphocytes in colorectal cancer liver metastases. Expert Opinion on Therapeutic Targets, 2015, 19, 147-161. | 1.5 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Macrophage Inhibitory Cytokine-1: A review of its pleiotropic actions in cancer. Cancer Biomarkers, 2012, 11, 183-190. | 0.8 | 27 |
| 56 | Helios expression in FoxP3<sup>+</sup>T regulatory cells. Expert Opinion on Biological Therapy, 2012, 12, 1423-1425. | 1.4 | 27 |
| 57 | Cd8 T-cell recognition of human 5T4 oncofetal antigen. International Journal of Cancer, 2006, 119, 1638-1647. | 2.3 | 26 |
| 58 | 5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype. Leukemia, 2012, 26, 1487-1498. | 3.3 | 25 |
| 59 | Differential gene expression of tumor-infiltrating CD8<sup>+</sup>T cells in advanced versus early-stage colorectal cancer and identification of a gene signature of poor prognosis. , 2020, 8, e001294. | | 25 |
| 60 | Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment. Cancer Immunology, Immunotherapy, 2021, 70, 2103-2121. | 2.0 | 23 |
| 61 | CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells. Cancer Immunology, Immunotherapy, 2008, 57, 833-847. | 2.0 | 22 |
| 62 | SnoRNAs and miRNAs Networks Underlying COVID-19 Disease Severity. Vaccines, 2021, 9, 1056. | 2.1 | 22 |
| 63 | DNA methylation in the promoters of PD-L1, MMP9, ARG1, galectin-9, TIM-3, VISTA and TGF-Î² genes in HLA-DR<sup>â€“</sup> myeloid cells, compared with HLA-DR<sup>+</sup> antigen-presenting cells. Epigenetics, 2020, 15, 1275-1288. | 1.3 | 21 |
| 64 | An evaluation of sorter induced cell stress (SICS) on peripheral blood mononuclear cells (PBMCs) after different sort conditions - Are your sorted cells getting SICS?. Journal of Immunological Methods, 2020, 487, 112902. | 0.6 | 19 |
| 65 | Transcriptomic Profiling of Tumor-Infiltrating CD4+TIM-3+ T Cells Reveals Their Suppressive, Exhausted, and Metastatic Characteristics in Colorectal Cancer Patients. Vaccines, 2020, 8, 71. | 2.1 | 19 |
| 66 | Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy. Expert Opinion on Biological Therapy, 2008, 8, 385-395. | 1.4 | 18 |
| 67 | Thymus-Derived, Peripherally Derived, and in vitro-Induced T Regulatory Cells. Frontiers in Immunology, 2014, 5, 17. | 2.2 | 18 |
| 68 | Effect of pembrolizumab on CD4+CD25+, CD4+LAP+ and CD4+TIM-3+ T cell subsets. Clinical and Experimental Immunology, 2019, 196, 345-352. | 1.1 | 17 |
| 69 | Pembrolizumab Interferes with the Differentiation of Human FOXP3+â€“Induced T Regulatory Cells, but Not with FOXP3 Stability, through Activation of mTOR. Journal of Immunology, 2020, 204, 199-211. | 0.4 | 17 |
| 70 | Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-Î± versus IFN-Î±. Oncotarget, 2015, 6, 4428-4439. | 0.8 | 17 |
| 71 | Role of Regulatory T Cells in Allergy: Implications for Therapeutic Strategy. Inflammation and Allergy: Drug Targets, 2006, 5, 211-217. | 1.8 | 16 |
| 72 | Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitorâ€”An Opportunity for Cancer Treatment. Cells, 2020, 9, 33. | 1.8 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential. Expert Opinion on Therapeutic Targets, 2020, 24, 1251-1262. | 1.5 | 16 |
| 74 | Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population. Frontiers in Immunology, 2021, 12, 707159. | 2.2 | 16 |
| 75 | Differential gene expression of tumor-infiltrating CD33+ myeloid cells in advanced- versus early-stage colorectal cancer. Cancer Immunology, Immunotherapy, 2021, 70, 803-815. | 2.0 | 15 |
| 76 | SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities. Cancers, 2020, 12, 2186. | 1.7 | 14 |
| 77 | Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants. Genes, 2020, 11, 703. | 1.0 | 14 |
| 78 | Inhibitory Immune Checkpoint Receptors and Ligands as Prognostic Biomarkers in COVID-19 Patients. Frontiers in Immunology, 2022, 13, 870283. | 2.2 | 14 |
| 79 | Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer. International Immunology, 2005, 17, 1315-1325. | 1.8 | 13 |
| 80 | Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer. Clinical Immunology, 2006, 120, 91-98. | 1.4 | 13 |
| 81 | Circulating Regulatory T Cells in Endometrial Cancer: A Role for Age and Menopausal Status. Immunological Investigations, 2011, 40, 62-75. | 1.0 | 12 |
| 82 | Myeloid Cells in Circulation and Tumor Microenvironment of Colorectal Cancer Patients with Early and Advanced Disease Stages. Journal of Immunology Research, 2020, 2020, 1-10. | 0.9 | 12 |
| 83 | Differential expression of TIM-3 in circulation and tumor microenvironment of colorectal cancer patients. Clinical Immunology, 2020, 215, 108429. | 1.4 | 12 |
| 84 | Immunology and immunotherapy approaches for prostate cancer. Prostate Cancer and Prostatic Diseases, 2007, 10, 224-236. | 2.0 | 11 |
| 85 | Epigenetic regulation of immune checkpoints and TÂcell exhaustion markers in tumor-infiltrating T cells of colorectal cancer patients. Epigenomics, 2020, 12, 1871-1882. | 1.0 | 11 |
| 86 | Tumor-Infiltrating Lymphoid Cells in Colorectal Cancer Patients with Varying Disease Stages and Microsatellite Instability-High/Stable Tumors. Vaccines, 2021, 9, 64. | 2.1 | 11 |
| 87 | Comparison of Myeloid Cells in Circulation and in the Tumor Microenvironment of Patients with Colorectal and Breast Cancers. Journal of Immunology Research, 2017, 2017, 1-8. | 0.9 | 10 |
| 88 | Investigation of the Effect of PD-L1 Blockade on Triple Negative Breast Cancer Cells Using Fourier Transform Infrared Spectroscopy. Vaccines, 2019, 7, 109. | 2.1 | 10 |
| 89 | Role of circular RNAs in colorectal tumor microenvironment. Biomedicine and Pharmacotherapy, 2021, 137, 111351. | 2.5 | 10 |
| 90 | T-Regulatory Cells in Health and Disease. Journal of Immunology Research, 2018, 2018, 1-2. | 0.9 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Comment on â€œExpression of Helios in Peripherally Induced Foxp3+ Regulatory T Cellsâ€• Journal of Immunology, 2012, 189, 500.1-500. | 0.4 | 8 |
| 92 | RNA-Seq Analysis of Colorectal Tumor-Infiltrating Myeloid-Derived Suppressor Cell Subsets Revealed Gene Signatures of Poor Prognosis. Frontiers in Oncology, 2020, 10, 604906. | 1.3 | 8 |
| 93 | Circulating and Tumor-Infiltrating Immune Checkpoint-Expressing CD8+ Treg/T Cell Subsets and Their Associations with Disease-Free Survival in Colorectal Cancer Patients. Cancers, 2022, 14, 3194. | 1.7 | 8 |
| 94 | 5T4 as a target for immunotherapy in renal cell carcinoma. Expert Review of Anticancer Therapy, 2009, 9, 1705-1709. | 1.1 | 7 |
| 95 | In vitroeffect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells. Expert Opinion on Pharmacotherapy, 2014, 15, 1489-1499. | 0.9 | 7 |
| 96 | Transcriptomic Analyses of Myeloid-Derived Suppressor Cell Subsets in the Circulation of Colorectal Cancer Patients. Frontiers in Oncology, 2020, 10, 1530. | 1.3 | 7 |
| 97 | Integrated whole transcriptome and small RNA analysis revealed multiple regulatory networks in colorectal cancer. Scientific Reports, 2021, 11, 14456. | 1.6 | 7 |
| 98 | Associations of different immune checkpoints-expressing CD4+ Treg/ T cell subsets with disease-free survival in colorectal cancer patients. BMC Cancer, 2022, 22, . | 1.1 | 7 |
| 99 | Differential gene expression of tumor-infiltrating CD4 <sup>+</sup> T cells in advanced versus early stage colorectal cancer and identification of a gene signature of poor prognosis. OncoImmunology, 2020, 9, 1825178. | 2.1 | 6 |
| 100 | Exosomes: Biological Carriers and Promising Tools for Cancer Immunotherapy. Vaccines, 2020, 8, 390. | 2.1 | 5 |
| 101 | Transcriptome of Tumor-Infiltrating T Cells in Colorectal Cancer Patients Uncovered a Unique Gene Signature in CD4+ T Cells Associated with Poor Disease-Specific Survival. Vaccines, 2021, 9, 334. | 2.1 | 5 |
| 102 | Role of T Regulatory Cells and Myeloid-Derived Suppressor Cells in COVID-19. Journal of Immunology Research, 2022, 2022, 1-13. | 0.9 | 5 |
| 103 | Bead-isolated human CD4+CD25+ T regulatory cells are anergic and significantly suppress proliferation of CD4+CD25â^' T responder cells. Clinical Immunology, 2006, 120, 232-233. | 1.4 | 4 |
| 104 | Associations of Complete Blood Count Parameters with Disease-Free Survival in Right- and Left-Sided Colorectal Cancer Patients. Journal of Personalized Medicine, 2022, 12, 816. | 1.1 | 4 |
| 105 | Novel Therapeutic Strategies by Regulatory T Cells in Allergy. Chemical Immunology and Allergy, 2008, 94, 150-157. | 1.7 | 3 |
| 106 | Downregulation of Immunosuppressive Environment in Patients with Chronic HBV Hepatitis on Maintained Remission. Frontiers in Immunology, 2015, 6, 52. | 2.2 | 3 |
| 107 | Transcriptome of CD8+ tumor-infiltrating T cells: a link between diabetes and colorectal cancer. Cancer Immunology, Immunotherapy, 2021, 70, 2625-2638. | 2.0 | 3 |
| 108 | Editorial: CD4+ T Cells in Cancer Immunotherapies. Frontiers in Immunology, 2021, 12, 737615. | 2.2 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Novel IFNÎ³ ELISPOT Assay for Detection of Functional Carcinoembryonic Antigenâ€Specific Chimeric Antigen Receptorâ€Redirected T Cells. Scandinavian Journal of Immunology, 2011, 74, 419-422. | 1.3 | 2 |
| 110 | Editorial of Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine. Vaccines, 2020, 8, 376. | 2.1 | 2 |
| 111 | Transcriptomic Profiling of Circulating HLA-DR<sup>â€“</sup> Myeloid Cells, Compared with HLA-DR<sup>+</sup> Myeloid Antigen-presenting Cells. Immunological Investigations, 2021, 50, 952-963. | 1.0 | 2 |
| 112 | Correlations between Circulating and Tumor-Infiltrating CD4+ T Cell Subsets with Immune Checkpoints in Colorectal Cancer. Vaccines, 2022, 10, 538. | 2.1 | 2 |
| 113 | F.134. Increased Population of CD4+CD25high Regulatory T-Cells in the Peripheral Blood of Renal Cell Carcinoma Patients. Clinical Immunology, 2006, 119, S98. | 1.4 | 0 |
| 114 | A combination of T regulatory cell-specific markers to determine the expanded subsets in cancer patients. European Journal of Cancer, 2016, 61, S209. | 1.3 | 0 |
| 115 | Intrinsic and acquired cancer immunotherapy resistance. , 2022, , 463-497. | | 0 |
| 116 | Abstract 3632: Targeting of tumor myeloid suppressor cells by Salmonella bacteria causes a shift to M1 phenotype and leads to inhibition of tumor growth. , 2014, , . | | 0 |
| 117 | Combining FoxP3 and Helios with GARP/LAP markers to identify expanded Treg subsets in cancer patients.. Journal of Clinical Oncology, 2016, 34, e23118-e23118. | 0.8 | 0 |
| 118 | Abstract 4102: DNA methylation and repressive histones in the promoters of immune checkpoints in tumor tissues and peripheral blood of breast and colorectal cancer patients. , 2019, , . | | 0 |